Details:
Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Lead Product(s): ACH000029
Therapeutic Area: Psychiatry/Psychology Product Name: ACH000029
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: McQuade Center for Strategic Research and Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2021